46
views
0
recommends
+1 Recommend
2 collections
    0
    shares

      Call for Papers: Supportive Care - Essential for Modern Oncology

      Submit here before December 31, 2024

      About Oncology Research and Treatment: 2.0 Impact Factor I 3.2 CiteScore I 0.521 Scimago Journal & Country Rank (SJR)

      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Rapid Malignant Transformation of Tubulovillous Adenoma, Initially Presenting as McKittrick-Wheelock Syndrome: A Case Report

      case-report

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Most cases of colorectal cancer develop from adenomatous polyps, slowly progressing within an average period of 8–10 years. McKittrick-Wheelock syndrome (MKWS) is a rare manifestation of tubulovillous adenoma. It generally presents as hypersecretory diarrhea with severe electrolyte and fluid depletion. Roughly, 5% of the published cases have reported malignant histopathology associated with MKWS, with little to no data regarding the malignant transformation process of those patients. Our patient was a 53-year-old Asian woman suffering from chronic secretory diarrhea, resulting in severe volume, electrolyte depletion, and prerenal azotemia, consistent for MKWS. Her symptoms initially improved with sulfasalazine but eventually worsened. She demonstrated signs of systemic (elevated leukocyte, CRP, and LDH) and local inflammation (dense lymphocyte infiltration in colorectal tissue) throughout the course of her disease. Serial pathological results showed rapid neoplastic progression of adenomatous polyp to adenocarcinoma within 1 year period. Surgical resection resulted in complete symptom resolution. Molecular examination showed a favorable profile of exon 4 Kirsten rat sarcoma viral oncogene homolog mutation, normal NRAS, BRAF, CDX2, and CK20 expressions. Her molecular pattern did not reflect the profile of an aggressive disease, suggesting the possibility of oncogenic processes outside the major pathways of adenoma to carcinoma progression. Chronic inflammation is a well-established risk factor for colorectal cancer, and prostaglandin E2 (PGE2) has been observed as one of the key regulators of tumor initiation and growth. PGE2 is also responsible for hypersecretory diarrhea associated with MKWS.

          Related collections

          Most cited references27

          • Record: found
          • Abstract: found
          • Article: not found

          The inflammatory pathogenesis of colorectal cancer

          The mutational landscape of colorectal cancer (CRC) does not enable predictions to be made about the survival of patients or their response to therapy. Instead, studying the polarization and activation profiles of immune cells and stromal cells in the tumour microenvironment has been shown to be more informative, thus making CRC a prototypical example of the importance of an inflammatory microenvironment for tumorigenesis. Here, we review our current understanding of how colon cancer cells interact with their microenvironment, comprised of immune cells, stromal cells and the intestinal microbiome, to suppress or escape immune responses and how inflammatory processes shape the immune pathogenesis of CRC.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Pathways of Colorectal Carcinogenesis

            Colorectal cancer is a heterogeneous disease that develops via stepwise accumulation of well-characterized genetic and epigenetic alterations. We review the genetic changes associated with the development of pre-cancerous colorectal adenomas and their progression to tumors, as well as the effects of defective DNA repair, chromosome instability, microsatellite instability, and alterations in the serrated pathway and DNA methylation. We provide insights into the different molecular subgroups of colorectal tumors that develop via each of these different mechanisms and their associations with patient outcomes.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer.

              Mutational analysis of KRAS codons 12 and 13 is standard for patients with metastatic colorectal cancer since mutations in these codons predict lack of response to anti-EGFR therapies. However, even among patients whose tumors are wildtype for KRAS codons 12 and 13, only a subset respond to therapy. Since additional activating mutations downstream of EGFR may also play a role in treatment resistance, we sought to establish the frequency of these mutations. We evaluated 2121 colorectal tumors for mutations in codons 12 and 13 of the KRAS gene. A subset of these samples, comprised of 513 samples wildtype for KRAS codons 12 and 13, were tested for mutations in codons 61 and 146 of KRAS, codon 600 of BRAF, and codons 12, 13, and 61 of NRAS. Mutation status was determined by targeted pyrosequencing. Mutations in KRAS codon 12 or 13 were identified in 900/2121 (42.4%) samples. Of the 513 wildtype samples tested for additional mutations, 78 samples were mutant for BRAF, 19 for KRAS codon 61, 17 for KRAS codon 146, and 26 for NRAS. In total, 140/513 (27.3%) tumors wildtype for KRAS codons 12 and 13 harbored a mutation in another of the RAS pathway genes. While further study is needed to determine the full therapeutic implications of mutations in these codons, mutational testing of these codons may be useful for identifying a significant proportion of patients who may also be resistant to anti-EGFR therapies. 2011 Wiley-Liss, Inc.
                Bookmark

                Author and article information

                Journal
                Case Rep Oncol
                Case Rep Oncol
                CRO
                CRO
                Case Reports in Oncology
                S. Karger AG (Basel, Switzerland )
                1662-6575
                4 September 2023
                Jan-Dec 2023
                4 September 2023
                : 16
                : 1
                : 818-826
                Affiliations
                [a ]Division of Hematology and Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Public Health, and Nursing, Dr. Sardjito Hospital, Gadjah Mada University, Yogyakarta, Indonesia
                [b ]Department of Internal Medicine, Faculty of Medicine, Public Health, and Nursing, Dr. Sardjito Hospital, Gadjah Mada University, Yogyakarta, Indonesia
                [c ]Department of Radiology, Faculty of Medicine, Public Health, and Nursing, Dr. Sardjito Hospital, Gadjah Mada University, Yogyakarta, Indonesia
                [d ]Department of Surgery, Faculty of Medicine, Public Health, and Nursing, Dr. Sardjito Hospital, Gadjah Mada University, Yogyakarta, Indonesia
                [e ]Department of Pathological Anatomy, Faculty of Medicine, Public Health, and Nursing, Dr. Sardjito Hospital, Gadjah Mada University, Yogyakarta, Indonesia
                [f ]Division of Gastroenterology and Hepatology, Department of Internal Medicine, Faculty of Medicine, Public Health, and Nursing, Dr. Sardjito Hospital, Gadjah Mada University, Yogyakarta, Indonesia
                Author notes
                Correspondence to: Neneng Ratnasari, nenengratnasari@ 123456mail.ugm.ac.id or Ibnu Purwanto, ibnupurwanto@ 123456ugm.ac.id
                Article
                531992
                10.1159/000531992
                10601724
                37900797
                7b21b352-73f9-4960-a625-eb63526785df
                © 2023 The Author(s). Published by S. Karger AG, Basel

                This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC) ( http://www.karger.com/Services/OpenAccessLicense). Usage and distribution for commercial purposes requires written permission.

                History
                : 2 June 2023
                : 7 July 2023
                : 2023
                Page count
                Figures: 7, References: 27, Pages: 9
                Funding
                No funding was received specifically for this case report.
                Categories
                Case Report

                Oncology & Radiotherapy
                tubulovillous adenoma,malignant transformation,kirsten rat sarcoma viral oncogene homolog,mckittrick-wheelock syndrome,inflammation

                Comments

                Comment on this article